Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 465

1.

A Randomized Phase 2 Study Of Ganetespib, A Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Second-Line Therapy Of Advanced Non-Small-Cell Lung Cancer (GALAXY-1).

Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D.

Ann Oncol. 2015 May 21. pii: mdv220. [Epub ahead of print]

PMID:
25997818
2.

A phase 1 study of ABT-806 in subjects with advanced solid tumors.

Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, Pedersen M, Ansell P, Ames W, Xiong H, Munasinghe W, Dudley M, Reilly EB, Holen K, Humerickhouse R.

Invest New Drugs. 2015 Jun;33(3):671-8. doi: 10.1007/s10637-015-0234-6. Epub 2015 Apr 17.

PMID:
25895099
3.

A MSFD complementary approach for the assessment of pressures, knowledge and data gaps in Southern European Seas: The PERSEUS experience.

Crise A, Kaberi H, Ruiz J, Zatsepin A, Arashkevich E, Giani M, Karageorgis AP, Prieto L, Pantazi M, Gonzalez-Fernandez D, Ribera d'Alcalà M, Tornero V, Vassilopoulou V, Durrieu de Madron X, Guieu C, Puig P, Zenetos A, Andral B, Angel D, Altukhov D, Ayata SD, Aktan Y, Balcıoğlu E, Benedetti F, Bouchoucha M, Buia MC, Cadiou JF, Canals M, Chakroun M, Christou E, Christidis MG, Civitarese G, Coatu V, Corsini-Foka M, Cozzi S, Deidun A, Dell'Aquila A, Dogrammatzi A, Dumitrache C, Edelist D, Ettahiri O, Fonda-Umani S, Gana S, Galgani F, Gasparini S, Giannakourou A, Gomoiu MT, Gubanova A, Gücü AC, Gürses Ö, Hanke G, Hatzianestis I, Herut B, Hone R, Huertas E, Irisson JO, İşinibilir M, Jimenez JA, Kalogirou S, Kapiris K, Karamfilov V, Kavadas S, Keskin Ç, Kideyş AE, Kocak M, Kondylatos G, Kontogiannis C, Kosyan R, Koubbi P, Kušpilić G, La Ferla R, Langone L, Laroche S, Lazar L, Lefkaditou E, Lemeshko IE, Machias A, Malej A, Mazzocchi MG, Medinets V, Mihalopoulos N, Miserocchi S, Moncheva S, Mukhanov V, Oaie G, Oros A, Öztürk AA, Öztürk B, Panayotova M, Prospathopoulos A, Radu G, Raykov V, Reglero P, Reygondeau G, Rougeron N, Salihoglu B, Sanchez-Vidal A, Sannino G, Santinelli C, Secrieru D, Shapiro G, Simboura N, Shiganova T, Sprovieri M, Stefanova K, Streftaris N, Tirelli V, Tom M, Topaloğlu B, Topçu NE, Tsagarakis K, Tsangaris C, Tserpes G, Tuğrul S, Uysal Z, Vasile D, Violaki K, Xu J, Yüksek A, Papathanassiou E.

Mar Pollut Bull. 2015 Apr 16. pii: S0025-326X(15)00169-1. doi: 10.1016/j.marpolbul.2015.03.024. [Epub ahead of print]

4.

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, Pandya SS, Millham R, Borzillo G, Pierce KJ, Han L, Houk BE, Gallo JD, Alsina M, Braña I, Tabernero J.

Clin Cancer Res. 2015 Apr 15;21(8):1888-95. doi: 10.1158/1078-0432.CCR-14-1306. Epub 2015 Feb 4.

PMID:
25652454
5.

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Berzofsky JA, Hsu FJ, Guitart J.

Cancer Immunol Immunother. 2015 Apr;64(4):437-46. doi: 10.1007/s00262-015-1653-0. Epub 2015 Jan 13.

PMID:
25579378
6.

Effect of patient navigation on colorectal cancer screening in a community-based randomized controlled trial of urban African American adults.

Horne HN, Phelan-Emrick DF, Pollack CE, Markakis D, Wenzel J, Ahmed S, Garza MA, Shapiro GR, Bone LR, Johnson LB, Ford JG.

Cancer Causes Control. 2015 Feb;26(2):239-46. doi: 10.1007/s10552-014-0505-0. Epub 2014 Dec 17.

PMID:
25516073
7.

Recovery trajectories after burn injury in young adults: does burn size matter?

Ryan CM, Lee A, Kazis LE, Schneider JC, Shapiro GD, Sheridan RL, Meyer WJ, Palmieri T, Pidcock FS, Reilly D, Tompkins RG; Multicenter Burn Outcome Group.

J Burn Care Res. 2015 Jan-Feb;36(1):118-29. doi: 10.1097/BCR.0000000000000214.

PMID:
25501787
8.

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL.

Clin Cancer Res. 2015 Feb 15;21(4):925-33. doi: 10.1158/1078-0432.CCR-14-0842. Epub 2014 Dec 5.

PMID:
25480831
9.

Serum uric acid as a clinically useful nutritional marker and predictor of outcome in maintenance hemodialysis patients.

Beberashvili I, Sinuani I, Azar A, Shapiro G, Feldman L, Stav K, Sandbank J, Averbukh Z.

Nutrition. 2015 Jan;31(1):138-47. doi: 10.1016/j.nut.2014.06.012. Epub 2014 Jul 18.

PMID:
25466658
10.

Maternal blood metal levels and fetal markers of metabolic function.

Ashley-Martin J, Dodds L, Arbuckle TE, Ettinger AS, Shapiro GD, Fisher M, Taback S, Bouchard MF, Monnier P, Dallaire R, Fraser WD.

Environ Res. 2015 Jan;136:27-34. doi: 10.1016/j.envres.2014.10.024. Epub 2014 Nov 20.

11.

The biology and clinical development of MEK inhibitors for cancer.

Luke JJ, Ott PA, Shapiro GI.

Drugs. 2014 Dec;74(18):2111-28. doi: 10.1007/s40265-014-0315-4.

PMID:
25414119
12.

Committee for Tactical Emergency Casualty Care (C-TECC) Update: Summer 2014.

Callaway DW, Smith R, Shapiro G, McKay S.

J Spec Oper Med. 2014 Fall;14(3):134-9. No abstract available.

PMID:
25344722
13.

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.

Shapiro GI, Kwak E, Dezube BJ, Yule M, Ayrton J, Lyons J, Mahadevan D.

Clin Cancer Res. 2015 Jan 1;21(1):87-97. doi: 10.1158/1078-0432.CCR-14-0979. Epub 2014 Oct 21.

PMID:
25336693
14.

A birth cohort study to investigate the association between prenatal phthalate and bisphenol A exposures and fetal markers of metabolic dysfunction.

Ashley-Martin J, Dodds L, Arbuckle TE, Ettinger AS, Shapiro GD, Fisher M, Morisset AS, Taback S, Bouchard MF, Monnier P, Dallaire R, Fraser WD.

Environ Health. 2014 Oct 22;13:84. doi: 10.1186/1476-069X-13-84.

15.

A response to Fu et al.'s "Educational interventions to increase HPV vaccination acceptance".

Shapiro GK, Joyal-Desmarais K, Perez S, Rosberger Z.

Vaccine. 2014 Nov 12;32(48):6342-4.

PMID:
25306910
16.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ.

N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.

17.

Co-responding Police-Mental Health Programs: A Review.

Shapiro GK, Cusi A, Kirst M, O'Campo P, Nakhost A, Stergiopoulos V.

Adm Policy Ment Health. 2014 Sep 20. [Epub ahead of print]

PMID:
25239523
18.

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.

Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM.

Clin Cancer Res. 2015 Jan 1;21(1):60-7. doi: 10.1158/1078-0432.CCR-14-0607. Epub 2014 Sep 17.

PMID:
25231399
19.

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

Dahlberg SE, Shapiro GI, Clark JW, Johnson BE.

J Natl Cancer Inst. 2014 Jun 24;106(7). pii: dju163. doi: 10.1093/jnci/dju163. Print 2014 Jul.

PMID:
24963024
20.

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.

Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, Graham A, Busman T, Mabry M, Holen K, Shapiro GI, Uronis H.

Invest New Drugs. 2014 Oct;32(5):937-45. doi: 10.1007/s10637-014-0110-9. Epub 2014 Jun 11.

PMID:
24916770
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk